China Drug Approvals

China: NMPA Approves New Therapies | 2026

Badari Andukuri

Aug 26

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

Badari Andukuri

Jul 23

Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter

Badari Andukuri

Jul 8

China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter

Badari Andukuri

Jun 19

Exdensur (depemokimab) wins NMPA approval in China for severe eosinophilic asthma

Badari Andukuri

Apr 4

China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter

ipharmaservices

Jan 23

China Grants Approval to Nucala for COPD Management | iPharmaCenter

ipharmaservices

Jan 7

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

Badari Andukuri

Dec 31, 2025

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Badari Andukuri

Nov 28, 2025

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

ipharmaservices

Jan 7, 2025

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

ipharmaservices

Jan 7, 2025

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

ipharmaservices

Dec 7, 2024

HUTCHMED Announces Continued Inclusion of Savolitinib in China’s National Reimbursement Drug List at Current Terms | China NRDL 2024 | iPharmaCenter

ipharmaservices

Dec 7, 2024

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

ipharmaservices

Dec 7, 2024

AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter

ipharmaservices

Oct 14, 2024

China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter

ipharmaservices

Aug 24, 2024

Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter

ipharmaservices

Aug 13, 2024

HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Jul 8, 2024

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

ipharmaservices

Jul 2, 2024

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 26, 2024

China: NMPA Approves New Therapies | 2026

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter

China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter

Exdensur (depemokimab) wins NMPA approval in China for severe eosinophilic asthma

China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter

China Grants Approval to Nucala for COPD Management | iPharmaCenter

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

HUTCHMED Announces Continued Inclusion of Savolitinib in China’s National Reimbursement Drug List at Current Terms | China NRDL 2024 | iPharmaCenter

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter

China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter

Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter

HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

Join our mailing list